Catabasis Pharma (CATB) Tops Q4 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Recent Corporate Developments
March 2, 2016 4:01 PM EST-- CAT-1004: Positive Top-Line MoveDMDSM Part A Results in Duchenne Muscular Dystrophy --
-- CAT-2054: Phase 2a Trial in Hypercholesterolemia Progressing On Schedule --
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter ended December 31, 2015 and... More
